personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Intracameral bevacizumab for intraocular pressure control in patients with neovascular glaucoma

Session Details

Session Title: Vascular Diseases & Anterior/posterior segment surgery

Session Date/Time: Sunday 29/09/2013 | 11:00-13:00

Paper Time: 11:24

Venue: Hall 3 (Level 0)

First Author: A.Souka EGYPT

Co Author(s):    S. Soliman              

Abstract Details


To document changes in intraocular pressure (IOP) and grade if iris neovascularization (NVI) in patients with neovascular glaucoma (NVG) after Intracameral bevacizumab injection as an anti-vascular endothelial growth factor (VEGF); the cause of new vessel formation.


Faculty of Medicine, Alexandria Main University Hospital (iris photography and follow up) i-Care eye Hospital (intracameral injection)


A retrospective review of eyes with NVG that were injected by single intracameral bevacizumab injection (2.5 mg/0.1ml), IOP measurements and NVI grading with Laatikainen Grading system were done and compared both preoperatively and post operatively.


12 eyes of 10 patients with NVG were injected. Eyes with pre-injection IOP ≤ 21 mmHg show stability throughout follow up period (3 months) while eyes with IOP > 21 mmHg showed a significant (p<0.0001) decrease in IOP. Regression of NVI was inversely proportional to pre-injection grade


Intracameral bevacizumab can be used to control high IOP in NVG.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy